SGN-CD19B, a Pyrrolobenzodiazepine (PBD)-Based Anti-CD19 Drug Conjugate, Demonstrates Potent Preclinical Activity Against B-Cell Malignancies

被引：3
|
作者：
Ryan, Maureen C. [1 ]
Schimpf, Brian [1 ]
Anderson, Martha [1 ]
Zeng, Weiping [1 ]
Emmerton, Kim [1 ]
Miyamoto, Jamie [1 ]
Kostner, Heather [1 ]
Yu, Changpu [1 ]
Van Epps, Heather [1 ]
Tatalick, Laurie [1 ]
Benjamin, Dennis [1 ]
机构：
[1] Seattle Genet Inc, Translat Res, Bothell, WA USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.594.594
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] IKS03, a Next Generation CD19-Targeted Antibody Drug Conjugate, Shows Potent Activity in Preclinical Models of Aggressive B-Cell Lymphomas
    Deckert, Jutta
    Thirlway, Jenny
    Mysliwy, Justyna
    Lodge, Adam
    Park, Yun-Hee
    Ryu, Hyun-Min
    Han, Na Ra
    Song, Ho Young
    Chung, Chul-Woong
    Lutz, Robert J.
    BLOOD, 2022, 140 : 3134 - 3135
  • [32] SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML
    Sutherland, May S. K.
    Walter, Roland B.
    Jeffrey, Scott C.
    Burke, Patrick J.
    Yu, Changpu
    Harrington, Kimberly H.
    Stone, Ivan
    Ryan, Maureen C.
    Sussman, Django
    Zeng, Weiping
    Benjamin, Dennis R.
    Bernstein, Irwin D.
    Senter, Peter D.
    Drachman, Jonathan G.
    McEarchern, Julie A.
    BLOOD, 2012, 120 (21)
  • [33] A novel antibody-drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity
    Jiang, Linlin
    Yang, Ming
    Zhang, Xiaoyun
    Bao, Shiqi
    Ma, Li
    Fan, Dongmei
    Zhou, Yuan
    Xiong, Dongsheng
    Zhen, Yongsu
    JOURNAL OF DRUG TARGETING, 2016, 24 (01) : 47 - 57
  • [34] Anti-CD19-CD22 antibody drug conjugate to reduce tumor recurrence in B-cell hematologic cancers.
    Du, Liang
    Wan, Tingting
    Jin, Yi
    Yuan, Jijun
    CANCER RESEARCH, 2022, 82 (12)
  • [35] An anti-CD20 extracellular antibody-drug conjugate for the treatment of B-cell malignancies
    Prudent, James R.
    Hall, Chad A.
    Marshall, David J.
    Murphy, John
    Harried, Scott
    CANCER RESEARCH, 2016, 76
  • [36] hLL2-Cys-PBD, a New Site-Specifically Conjugated, Pyrrolobenzodiazepine (PBD) Dimer-Based Antibody Drug Conjugate (ADC) Targeting CD22-Expressing B-Cell Malignancies.
    Zammarchi, Francesca
    Corbett, Simon
    Adams, Lauren
    Mellinas-Gomez, Maria
    Tyrer, Peter
    Dissanayake, Sandamali
    Sims, Simone
    Havenith, Karin
    Chivers, Simon
    Willimas, David G.
    Howard, Philip W.
    Hartley, John A.
    van Berkel, Patrick
    BLOOD, 2016, 128 (22)
  • [37] The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma
    Flavell, DJ
    Warnes, SL
    Bryson, CJ
    Field, SA
    Noss, AL
    Packham, G
    Flavell, SU
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 134 (02) : 157 - 170
  • [38] CD19-negative B-cell precursors in bone marrow: A potential mimicker for CD19-negative B-lymphoblastic leukemia by flow cytometry in patients with anti-CD19 treatment
    Li, Weijie
    Morgan, Ruth
    Nieder, Roxanne
    Habeebu, Sahibu Sultan M.
    Myers, G. Doug
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2023, 104 (05) : 392 - 396
  • [39] Efficacy of anti-CD19 CAR-T cell therapy in 10 refractory recurrent B cell malignancies
    包芳
    ChinaMedicalAbstracts(InternalMedicine), 2018, 35 (03) : 186 - 187
  • [40] A glycoengineered anti-CD19 antibody (MEDI-551) is effective as monotherapy or in combination treatment in mouse models of B-cell malignancies
    Ward, Beth K.
    Mittereder, N.
    Kuta, E.
    Sims, G.
    Damschroeder, M.
    Dall'Acqua, W.
    Bowen, M. A.
    Wu, H.
    Tedder, T. F.
    Kiener, P. A.
    Jallal, B.
    Coyle, T.
    Herbst, R.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
12345